Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + ipilimumab + nab-paclitaxel + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A four-drug combination regimen consisting of the immune checkpoint inhibitors nivolumab (a monoclonal antibody targeting PD-1) and ipilimumab (a monoclonal antibody targeting CTLA-4), combined with chemotherapy agents nab-paclitaxel (albumin-bound paclitaxel) and gemcitabine. This combination is under investigation primarily for pancreatic cancer, particularly advanced or metastatic pancreatic adenocarcinoma, in clinical trials. Nivolumab and ipilimumab work by blocking inhibitory pathways in T cells, thereby promoting immune-mediated antitumor activity. Nab-paclitaxel interferes with microtubule function, inhibiting cell division, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. Together, the regimen aims to combine immunotherapeutic and cytotoxic mechanisms to improve tumor control[1][3][5][7].
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nivolumab + ipilimumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + ipilimumab + nab-paclitaxel + gemcitabine.